RESEARCH / ONCOLOGY
Personalised cancer vaccines: what an early ovarian-cancer trial tells us
Promising immune activity is a research signal—not proof that a treatment improves survival.
The study
A phase 1 study published in Nature Medicine on 14 October 2026 tested personalised NeoVax vaccines with delayed anti-PD-1 treatment in ten patients with platinum-sensitive ovarian cancer after standard chemotherapy.
What researchers observed
No unexpected safety signals were reported, and no participants stopped treatment because of toxicity. Biomarker findings suggested vaccine activity in six of ten patients, alongside broader immune responses. The team also identified tumour-resistance mechanisms involving antigen presentation.
Why the limits matter
This was a small, early-phase study focused on feasibility and safety. Immune responses do not establish a survival benefit or justify replacing standard treatment. Larger controlled studies are needed to assess clinical benefit.
Read the original research
Sellars, Frank, Shim and colleagues. Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial. Nature Medicine, 2026.
Source: the published study and abstract. Educational research summary; not individual treatment advice.